Display search results for ** instead (461 products)

Showing 41-50 of 461

The Brexit vote’s impact on investment into UK technology start-ups is an important litmus test for broader implications for the UK economy. The UK’s technology sector is a huge driver of growth, performing markedly above the broader economy and with rapid job creation.

USD 500.00

USD 375.00 save 25 %

26 Sep 2016  |  Global

IoT Security: The Impossible Mission

2015 was the year for Internet of Things (IoT) in term of positive perspectives, growth potential, industry impacts, and new revenue sources. Frost & Sullivan revealed that by 2020, the total global market will reach over $200 billion and every household will have at least 10 connected devices. In the coming year, the construction market will emerg...

USD 500.00

USD 375.00 save 25 %

The race to fulfil the promise of a smart future — be it the benefits of smart mobility, smart energy, or smart cities — has kick-started rich veins of possible inventions. Start-ups jostle with established technologists for technology leadership and mindshare to enrich the necessary architecture for such smart systems, or the Internet of Thing...

USD 500.00

USD 375.00 save 25 %

Frost & Sullivan was invited to attend Fortinet’s 3rd EMEA 361° Security Forum in September and we took the opportunity to ask Mr. Michael Xie, Co-founder, President, and Chief Technology Officer (CTO), a few questions.

USD 500.00

USD 375.00 save 25 %

USD 500.00

USD 375.00 save 25 %

18 Mar 2016  |  North America

Vital Signs - Drug Development Focus on Genetically Modified Swine

Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs

The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states ...

USD 450.00

USD 337.50 save 25 %

18 Mar 2016  |  North America

Vital Signs - Stem Cell Therapy in Ischemic Stroke Recovery

Additional Clinical Trials Critical to Building on Early Promise

As indicated by the World Health Organization, stroke is the second-leading cause of death for people over the age of 60 and is the fifth-leading cause of death for those between the ages of 15 and 59. The incidence of stroke is expected to increase by 25% over the next 20 years. Over 40% of ischemic stroke victims have permanent symptoms and only ...

USD 450.00

USD 337.50 save 25 %

04 Apr 2016  |  Global

Vital Signs - Emerging Trends and Opportunities in Life Sciences, February 2016

Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes

This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.

USD 450.00

USD 337.50 save 25 %

05 Jan 2016  |  Global

Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise

This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.

USD 450.00

USD 337.50 save 25 %

Showing 41-50 of 461